Ronald D. Green has reported significant stock transactions in his recent SEC filing, which may have implications for Neogen Corp and the broader life sciences industry.

Background

Green Ronald D is associated with Neogen Corp, a company engaged in the life sciences sector. Neogen is classified under the SIC code for In Vitro & In Vivo Diagnostic Substances. The company is publicly traded under the ticker symbol NEOG on the appropriate exchanges.

What the Filing Says

The filing, dated October 2, 2026, details several transactions involving restricted stock units and common stock. Green acquired 9,804 restricted stock units at a price of $12.24 per share on October 1, 2026. Following this transaction, he owns a total of 28,458 shares.

Additionally, the filing indicates that Green exercised options to buy 20,558 shares of common stock at the same price of $12.24. These options are set to expire on October 1, 2036.

Impact

These transactions may affect Neogen Corp's market perception and investor confidence. The filing indicates that Green is a director of the company, which adds weight to his investment decisions. Other stakeholders, including shareholders and potential investors, may view these actions as a sign of confidence in Neogen's future performance.

What's Next

The filing does not say what happens next.